Johnson & Johnson plans to deliver 20 million doses of its COVID-19 vaccine candidate to the United States by the end of March if the Food and Drug Administration authorizes emergency use of the single-dose vaccine, a company executive told a House subcommittee today at a hearing on expanding vaccine availability.

An FDA advisory committee expects Friday to consider the emergency use application. If authorized for emergency use, the J&J candidate would be the third COVID-19 vaccine authorized for use in the United States, joining the Pfizer and Moderna vaccines. The departments of Health and Human Services and Defense in August agreed to purchase 100 million doses of the J&J vaccine candidate and could acquire up to 300 million additional doses under the agreement.

Related News Articles

Headline
The Food and Drug Administration July 15 announced a recall by Sandoz on certain lots of cefazolin, due to the lots being mislabeled as penicillin G potassium…
Headline
 The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
The Occupational Safety and Health Administration June 30 released a proposed rule to remove what remains of its emergency temporary standard for occupational…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…
Headline
Leaders of the Food and Drug Administration May 20 announced new guidelines for administering the COVID-19 vaccine in a paper published by the New England…
Headline
A study published April 8 by the Public Library of Science’s Journal of Global Public Health found that driving while infected with COVID-19 raises the risk of…